Cognetivity Neurosciences Ltd.
CGNSF · OTC
10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.43 | 0.22 | 0.18 | -0.06 |
| FCF Yield | -0.01% | -4.13% | -5.50% | -8.09% |
| EV / EBITDA | -20.03 | -23.47 | -29.37 | -13.16 |
| Quality | ||||
| ROIC | 6.35% | 7.48% | 15.11% | 23.32% |
| Gross Margin | -1,547.32% | 62.53% | -64.54% | 89.28% |
| Cash Conversion Ratio | -0.01 | 0.35 | 0.72 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 462,461.33% | 411,665.14% | 367,147.66% | 356,551.04% |
| Free Cash Flow Growth | 99.75% | 55.96% | 8.84% | -608.11% |
| Safety | ||||
| Net Debt / EBITDA | -1.93 | -1.78 | -0.66 | 0.63 |
| Interest Coverage | -0.66 | -0.76 | -1.00 | -1.65 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 560.53 | -9,243.36 | -16,668.47 | -38,461.88 |